Healthcare

With JP Morgan out of the way, it's time for the biotechnology space to return to normality. Well, normality, that is, as far as the biotech space can be normal. There remains a host of catalysts and data drops on the calendar, and these have the potential to drive...

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Advisory Board Co. (NASDAQ:ABCO) reported that Elliott Associates, L.p. has picked up 316,321 of common stock as of 2017-01-12. The acquisition brings the aggregate amount owned by Elliott Associates, L.p. to a total of 316,321...

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Kindred Biosciences Inc. (NASDAQ:KIN) reported that Park West Asset Management has picked up 2,274,138 of common stock as of 2017-01-12. The acquisition brings the aggregate amount owned by Park West Asset Management to a total...

We said it yesterday, and we'll say it again - biotech is ht right now. The JP Morgan conference is drawing to a close, and with it, we have seen a flurry of deals done and data drop. Here's the latest news form the institutional side of things, involving...

Xenetic Biosciences, Inc. (NASDAQ: XBIO), a clinical-stage biopharmaceutical company focused on the discovery, research & development of next-generation biologic drugs, announced that it received a $3 million milestone payment from Shire plc (LSE: SHP, NASDAQ:SHPG) related to Shire’s advancing the Phase 1/2a clinical study for the PSA-Recombinant SHP656 or Factor VIII...